Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Lumos Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS at Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Derm-Biome Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healis Therapeutics Announces Collaboration with Massachusetts General Hospital (MGH) and Affiliates of Harvard Medical School to Advance Clinical-Stage Neuroscience Research","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Massachusetts General Hospital

    Menu

    Massachusetts General Hospital

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Healis Therapeutics Announces Collaboration with Massachusetts General Hospital (MGH) and Affiliates of Harvard Medical School to Advance Clinical-Stage Neuroscience Resear...

              Details:

              The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions, including Major Depressive Disorder (MDD), PTSD, and Social Anxiety Disorder (SAD).

              Lead Product(s): CKDB-501A

              Therapeutic Area: Psychiatry/Psychology Product Name: CKDB-501A

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Healis Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study

              Details:

              The collaboration aims to study the second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Recipient: Derm-Biome Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS at Massachusetts General Hospital

              Details:

              TRP-8802 (Oral psilocybin) in patients withIrritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with Irritable Bowel Syndrome.

              Lead Product(s): Psilocybine

              Therapeutic Area: Gastroenterology Product Name: TRP-8802

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Tryp Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

              Details:

              NeuroSense & Massachusetts General Hospital will explore the neurotherapeutic effects of PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue. PrimeC is a novel unique fixed-dose combination of ciprofloxacin and celecoxib.

              Lead Product(s): Ciprofloxacin,Celecoxib

              Therapeutic Area: Neurology Product Name: PrimeC

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: NeuroSense Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Init...

              Details:

              Under the terms of the agreement, Harvard Medical School will initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

              Lead Product(s): Undislcosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Recipient: Voltron Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial

              Details:

              ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress granules.

              Lead Product(s): ABBV-CLS-7262

              Therapeutic Area: Neurology Product Name: ABBV-CLS-7262

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: AbbVie Inc

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 ...

              Details:

              LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.

              Lead Product(s): Ibutamoren

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LUM-201

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Lumos Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

              Details:

              SYN-020 is a recombinant bovine Intestinal Alkaline Phosphatase (IAP) formulated for oral delivery to the small intestine. The amended agreement include intellectual property and technology related to the use of SYN-020 intestinal alkaline phosphatase.

              Lead Product(s): Recombinant Bovine Intestinal Alkaline Phosphatase

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SYN-020

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Theriva Biologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: licensing agreement August 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Massachusetts General Hospital

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology

              Details:

              The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib.

              Lead Product(s): Abemaciclib

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Comprehensive Cancer Network

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding December 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY